These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 32002042)
1. A retrospective clinical research of relapsed organizing pneumonia. Yamagishi T; Kodaka N; Watanabe K; Nakano C; Oshio T; Niitsuma K; Shimada N; Matsuse H Ann Thorac Med; 2020; 15(1):15-20. PubMed ID: 32002042 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia. Xue M; Guo Z; Cai C; Sun B; Wang H Respiration; 2019; 98(6):534-545. PubMed ID: 31665737 [TBL] [Abstract][Full Text] [Related]
3. Rapidly progressive organizing pneumonia associated with COVID-19. Horii H; Kamada K; Nakakubo S; Yamashita Y; Nakamura J; Nasuhara Y; Konno S Respir Med Case Rep; 2020; 31():101295. PubMed ID: 33224726 [TBL] [Abstract][Full Text] [Related]
4. Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study. Xue C; Wu N; Li X; Qiu M; Du X; Ye Q BMC Pulm Med; 2017 Nov; 17(1):144. PubMed ID: 29149883 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of changes in the serum levels of Krebs von den Lungen-6 and surfactant protein-D over time as important biomarkers in idiopathic fibrotic nonspecific interstitial pneumonia. Yamakawa H; Hagiwara E; Ikeda S; Iwasawa T; Otoshi R; Tabata E; Okuda R; Sekine A; Baba T; Iso S; Okudela K; Takemura T; Ogura T Respir Investig; 2019 Sep; 57(5):422-429. PubMed ID: 31003951 [TBL] [Abstract][Full Text] [Related]
6. SP-D, KL-6, and HTI-56 levels in children with mycoplasma pneumoniae pneumonia. Shu LH; Lu Q; Han LY; Dong GH Int J Clin Exp Pathol; 2015; 8(9):11185-91. PubMed ID: 26617840 [TBL] [Abstract][Full Text] [Related]
7. The usefulness of KL-6 and SP-D for the diagnosis and management of chronic hypersensitivity pneumonitis. Okamoto T; Fujii M; Furusawa H; Tsuchiya K; Miyazaki Y; Inase N Respir Med; 2015 Dec; 109(12):1576-81. PubMed ID: 26481343 [TBL] [Abstract][Full Text] [Related]
10. Factors associated with the relapse of cryptogenic and secondary organizing pneumonia. Onishi Y; Kawamura T; Nakahara Y; Kagami R; Sasaki S; Takahashi S; Kominami R; Hirano K; Hiraoka R; Hirata N Respir Investig; 2017 Jan; 55(1):10-15. PubMed ID: 28012487 [TBL] [Abstract][Full Text] [Related]
11. Surfactant protein D: A useful biomarker for distinguishing COVID-19 pneumonia from COVID-19 pneumonia-like diseases. Togashi Y; Kono Y; Okuma T; Shioiri N; Mizushima R; Tanaka A; Ishiwari M; Toriyama K; Kikuchi R; Takoi H; Abe S Health Sci Rep; 2022 May; 5(3):e622. PubMed ID: 35509408 [TBL] [Abstract][Full Text] [Related]
12. Idiopathic Pulmonary Fibrosis Complicated by Adenocarcinoma and Organizing Pneumonia. Inutsuka Y; Yanagihara T; Matsumoto K; Yoneda R; Hashisako M; Ogo N; Asoh T; Maeyama T Cureus; 2022 Jan; 14(1):e20916. PubMed ID: 35004080 [TBL] [Abstract][Full Text] [Related]
13. KL-6 and surfactant proteins A and D in serum and bronchoalveolar lavage fluid in patients with acute eosinophilic pneumonia. Daimon T; Tajima S; Oshikawa K; Bando M; Ohno S; Sugiyama Y Intern Med; 2005 Aug; 44(8):811-7. PubMed ID: 16157978 [TBL] [Abstract][Full Text] [Related]
14. Predictive factors for relapse in corticosteroid-treated patients with chronic eosinophilic pneumonia. Takeuchi N; Arai T; Sasaki Y; Akira M; Matsuda Y; Tachibana K; Kasai T; Inoue Y J Thorac Dis; 2022 Nov; 14(11):4352-4360. PubMed ID: 36524087 [TBL] [Abstract][Full Text] [Related]
15. 18F-FDG Uptake in Less Affected Lung Field Provides Prognostic Stratification in Patients with Interstitial Lung Disease. Nobashi T; Kubo T; Nakamoto Y; Handa T; Koyasu S; Ishimori T; Mishima M; Togashi K J Nucl Med; 2016 Dec; 57(12):1899-1904. PubMed ID: 27339874 [TBL] [Abstract][Full Text] [Related]
16. Surfactant protein-D is more useful than Krebs von den Lungen 6 as a marker for the early diagnosis of interstitial pneumonitis during pegylated interferon treatment for chronic hepatitis C. Ishikawa T; Kubota T; Abe H; Hirose K; Nagashima A; Togashi T; Seki K; Honma T; Yoshida T; Kamimura T Hepatogastroenterology; 2012 Oct; 59(119):2260-3. PubMed ID: 23435141 [TBL] [Abstract][Full Text] [Related]
17. Serial change in serum biomarkers during treatment of Non-HIV Pneumocystis pneumonia. Urabe N; Sakamoto S; Sano G; Ito A; Sekiguchi R; Homma S J Infect Chemother; 2019 Dec; 25(12):936-942. PubMed ID: 31186197 [TBL] [Abstract][Full Text] [Related]
18. Predictors of Relapse in Patients with Organizing Pneumonia. Kim M; Cha SI; Seo H; Shin KM; Lim JK; Kim H; Yoo SS; Lee J; Lee SY; Kim CH; Park JY Tuberc Respir Dis (Seoul); 2015 Jul; 78(3):190-5. PubMed ID: 26175771 [TBL] [Abstract][Full Text] [Related]
19. Serum surfactant protein-A, but not surfactant protein-D or KL-6, can predict preclinical lung damage induced by smoking. Kobayashi H; Kanoh S; Motoyoshi K Biomarkers; 2008 Jun; 13(4):385-92. PubMed ID: 18595202 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic effects for hypersensitivity pneumonitis induced by Japanese mushroom (Bunashimeji). Tsushima K; Furuya S; Yoshikawa S; Yasuo M; Yamazaki Y; Koizumi T; Fujimoto K; Kubo K Am J Ind Med; 2006 Oct; 49(10):826-35. PubMed ID: 16948148 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]